Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women
LaCroix, Andrea Z × Powles, Trevor Osborne, C Kent Wolter, Kevin Thompson, John R Thompson, David D Allred, D Craig Armstrong, Róisín Cummings, Steve R Eastell, Richard Ensrud, Kristine E Goss, Paul Lee, Andrew Neven, Patrick Reid, David M Curto, Madelyn Vukicevic, Slobodan PEARL Investigators #
Oxford University Press
Journal of the National Cancer Institute vol:102 issue:22 pages:1706-15
Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene was shown to reduce the risk of estrogen receptor-positive (ER+) breast cancer, nonvertebral and vertebral fractures, coronary artery disease, and stroke, but the effects on total breast cancer (invasive and ductal carcinoma in situ, ER+ and estrogen receptor-negative [ER-]) and ER+ invasive breast cancer are unknown.